Synthetic biology for heparin biomanufacturing

作者：Yingjia Pan, Z. Lewis Liu, Peng Wang, Jian Gao, Junzhong Li, Binying Lv, Junyue Li, Junyue Li, Junyue Li, Xiangjiu Zhang, Liang Yin, Chang Dong, Jiaying Wang, Lei Huang, Jinshan Li, Jine Li, Jine Li, Jinshan Li, Jinshan Li, Zhinan Xu · 发表于：Bioresources and Bioprocessing · 年份：2026 · DOI：10.1186/s40643-025-00999-x · 被引用次数：1 · 研究领域：Proteoglycans and glycosaminoglycans research、Enzyme Production and Characterization、Liver physiology and pathology

Heparin, mainly used as an anticoagulant, has also shown potential in the treatment of diseases such as inflammation and cancer. Currently, heparin is mainly extracted from the intestinal mucosa of pigs. However, due to concerns about disease transmission and contamination associated with animal-derived products, biomanufacturing techniques have been explored as alternative production methods. Through enzyme engineering, metabolic engineering, and synthetic biology approaches, the heparin biosynthetic pathways have been systematically optimized. The main biomanufacturing techniques include in vivo/in vitro combination strategy (microbial heparosan fermentation followed by chemoenzymatic modification) and de novo biosynthesis. This article comprehensively discusses the latest advancements, challenges, and future perspectives of these heparin biomanufacturing techniques.